[Pharmacological correction by roxicam of the prostacyclin-thromboxane system in acute myocardial infarction complicated by heart failure].
The prostaglandin-thromboxane system, platelet hemostasis and central hemodynamics were evaluated in 51 patients with heart failure-complicated acute myocardial infarction during aspirin, roxicam and basic (nitrates + cardiac glycosides + diuretics) therapies. The new non-steroidal antiinflammatory agent roxicam was shown to selectively inhibit thromboxane, without affecting prostacyclin levels. The agent may be regarded as the drug of choice in using antiaggregatory therapy in patients with myocardial infarction concurrent with heart failure.
Shushliapin
O I
OI
Shelest
A N
AN
Khosseĭn Shakhavat
A F
AF
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D011464:Epoprostenol / Q000097:blood*; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D009566:Nitrates / Q000627:therapeutic use; D010894:Piroxicam / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood; D013931:Thromboxanes / Q000097:blood*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002301:Cardiac Glycosides; D004232:Diuretics; D009566:Nitrates; D013931:Thromboxanes; D010894:Piroxicam; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D001241:Aspirin
Farmakologicheskaia korrektsiia roksikamom prostatsiklin-tromboksanovoĭ sistemy pri ostrom infarkte miokarda, oslozhnennom serdechnoĭ nedostatochnost'iu.